<div id="readability-page-1"><div><p>Celltrion, Inc. (KOSE:A068270) proposed to acquire Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) on July 29, 2025. Celltrion, Inc. signed an agreement to acquire Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) for $330 million on September 22, 2025. Celltrion, Inc. plans to invest 700 billion won (approximately $503 million) for the acquisition, with the possibility of an additional 300 billion won for small-scale or up to 700 billion won for large-scale expansion, depending on market demand. Celltrion, Inc. will conduct due diligence before deciding on the final agreement and aims to complete the deal within the year if finalized.</p><p>  The transaction is expected to close by the end of this year.</p><p>Celltrion, Inc. (KOSE:A068270) completed the acquisition of Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) on January 2, 2026.</p></div></div>

礼来

<p>Celltrion, Inc. 已签署协议，以 3.3 亿美元收购礼来公司在美国的一处生物制药生产设施。该收购提议于 2025 年 7 月 29 日提出，涉及 7000 亿韩元（约合 5.03 亿美元）的投资，并可能根据市场需求进行额外投资。在最终确定协议之前，将进行尽职调查，预计交易将在 2025 年底完成。该收购于 2026 年 1 月 2 日完成</p>

Celltrion, Inc. 从礼来公司（NYSE：LLY）收购了美国的生物制药制造设施